Sensorineural deafness with dilated cardiomyopathy

Sensorineural deafness with dilated cardiomyopathy is an extremely rare genetic disorder characterized by the combination of sensorineural hearing loss and dilated cardiomyopathy (DCM). Sensorineural hearing loss results from damage to the inner ear (cochlea) or the auditory nerve pathways, leading to progressive or stable hearing impairment. Dilated cardiomyopathy involves enlargement and weakening of the heart's left ventricle, impairing its ability to pump blood efficiently, which can lead to heart failure, arrhythmias, and potentially sudden cardiac death. The condition thus primarily affects two organ systems: the auditory system and the cardiovascular system. The disease has been described in a small number of families, and its genetic basis has been linked to mutations that affect both cardiac and cochlear function. Onset can vary but has been reported in childhood or young adulthood. Patients may initially present with hearing difficulties, with cardiac symptoms such as fatigue, shortness of breath, and exercise intolerance developing subsequently or concurrently. Diagnosis typically involves audiometric testing to confirm sensorineural hearing loss and echocardiography or cardiac MRI to evaluate cardiac structure and function. There is currently no cure for this condition. Management is supportive and multidisciplinary, involving cardiologists and audiologists. Cardiac treatment follows standard heart failure protocols, including ACE inhibitors, beta-blockers, diuretics, and in severe cases, consideration of cardiac transplantation or implantable cardioverter-defibrillators. Hearing loss is managed with hearing aids or cochlear implants depending on severity. Regular cardiac monitoring is essential due to the progressive nature of the cardiomyopathy.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Sensorineural deafness with dilated cardiomyopathy